Orchid Cellmark Receives Second Nasdaq Delisting Notice for Missed Filing Deadline | GenomeWeb

NEW YORK, May 23 (GenomeWeb News) - Orchid Cellmark said yesterday that it received a delisting notice from Nasdaq on May 16 because it did not file its quarterly report for the period ended March 31 on time.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.